Cholecystokinin-2 Receptor Agonist 177Lu-PP-F11N for Radionuclide Therapy of Medullary Thyroid Carcinoma – Results of the Lumed Phase 0a Study

Rottenburger C¹, Nicolas GP¹, McDougall L¹, Kaul F¹, Cachovan M², Vija AH³, Schibli R⁴, Geistlich S⁵, Schumann A⁶, Rau T⁷, Glatz K⁸, Behe M⁵, Christ ER⁹, Wild D¹.

J Nucl Med. 2019 Sep 13. pii: jnumed.119.233031. doi: 10.2967/jnumed.119.233031.

1. Division of Nuclear Medicine, University Hospital Basel, Switzerland.
2. Siemens Healthcare GmbH, Forchheim, Germany, Germany.
3. Molecular Imaging, Siemens Medical Solutions USA, Inc., Hoffman Estates, IL, USA, United States.
4. Department of Chemistry and Applied Biosciences, Institute of Pharmaceutical Sciences, ETH, Switzerland.
5. Center for Radiopharmaceutical Sciences, Paul Scherrer Institute, Switzerland.
6. 3B Pharmaceuticals GmbH, Germany.
7. Institute of Pathology, University of Bern, Switzerland.
8. Institute of Pathology, University Hospital Basel, Switzerland.
9. Division of Endocrinology, Diabetology and Metabolism, University Hospital Basel, Switzerland.